{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=45", "query": { "intervention": "Injectable Placebo", "page": 45 }, "page_size": 10 }, "pagination": { "page": 45, "page_size": 10, "total_count": 4209, "total_pages": 421, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=46&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=44&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T12:46:59.060Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04133909", "title": "Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Mepolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 806, "start_date": "2019-10-30", "completion_date": "2024-08-08", "has_results": true, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-21T12:46:59.060Z", "location_count": 88, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 72 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04133909" }, { "nct_id": "NCT06957821", "title": "Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Carotid Artery Diseases", "Peripheral Arterial Disease" ], "interventions": [ { "name": "Pegulicianine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2026-06", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-21T12:46:59.060Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06957821" }, { "nct_id": "NCT05552326", "title": "A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Severe Hypertriglyceridemia" ], "interventions": [ { "name": "Olezarsen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 446, "start_date": "2022-08-31", "completion_date": "2025-09-12", "has_results": false, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-10-21T12:46:59.060Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Peoria, Arizona • Los Angeles, California + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05552326" }, { "nct_id": "NCT04081350", "title": "A Study of LY3471851 in Participants With Eczema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "LY3471851", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 48, "start_date": "2019-12-04", "completion_date": "2022-06-24", "has_results": false, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-10-21T12:46:59.060Z", "location_count": 20, "location_summary": "North Little Rock, Arkansas • Encinitas, California • Fremont, California + 17 more", "locations": [ { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04081350" }, { "nct_id": "NCT00345618", "title": "Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Embolism", "Thrombosis" ], "interventions": [ { "name": "Idrabiotaparinux sodium", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Placebo (for idrabiotaparinux sodium)", "type": "DRUG" }, { "name": "Avidin", "type": "DRUG" }, { "name": "Placebo (for warfarin)", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3202, "start_date": "2006-06", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2016-03-21", "last_synced_at": "2026-10-21T12:46:59.060Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00345618" }, { "nct_id": "NCT00808210", "title": "A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Infliximab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2009-03-05", "completion_date": "2012-11-14", "has_results": true, "last_update_posted_date": "2020-11-06", "last_synced_at": "2026-10-21T12:46:59.060Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Murrieta", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00808210" }, { "nct_id": "NCT05115110", "title": "A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Spinal Muscular Atrophy (SMA)" ], "interventions": [ { "name": "RO7204239", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Risdiplam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 97, "start_date": "2022-06-02", "completion_date": "2026-10-28", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-21T12:46:59.060Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05115110" }, { "nct_id": "NCT05528510", "title": "A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Guselkumab Dose 1", "type": "DRUG" }, { "name": "Guselkumab Dose 2", "type": "DRUG" }, { "name": "Guselkumab Dose 3", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 418, "start_date": "2022-09-13", "completion_date": "2028-10-06", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-21T12:46:59.060Z", "location_count": 32, "location_summary": "Litchfield Park, Arizona • Apple Valley, California • Lancaster, California + 26 more", "locations": [ { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Apple Valley", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05528510" }, { "nct_id": "NCT00918255", "title": "Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "adalimumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2009-04", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2011-05-09", "last_synced_at": "2026-10-21T12:46:59.060Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Bakerfield, California • Los Angeles, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakerfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00918255" }, { "nct_id": "NCT02483078", "title": "Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "PRO 140", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Optimized Background Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytoDyn, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2015-10", "completion_date": "2018-07", "has_results": true, "last_update_posted_date": "2022-11-03", "last_synced_at": "2026-10-21T12:46:59.060Z", "location_count": 34, "location_summary": "Fountain Valley, California • Long Beach, California • Los Angeles, California + 24 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02483078" } ] }